Nurix Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Insiders at Cue Biopharma (CUE), Nurix Therapeutics (NRIX), Flowers Foods (FLO), MarketAxess (MKTX), and Borr Drilling (BORR) made significant trades. Cue's CEO and other executives sold shares, while Borr Drilling's director made large purchases and sales. These moves may influence investor sentiment.
H.C. Wainwright raised its price target for Nurix Therapeutics (NASDAQ:NRIX) to $36, citing strong Q3 2026 results with $673.1M in revenue and $4.73 EPS. The firm noted increased expenses due to a Roche transaction but highlighted $1.1B in cash reserves. Analysts have mixed views on NRIX's growth potential, with price targets ranging from $33 to $41.
Nurix Therapeutics director Gregory Julia P sold 22,560 shares on October 14, 2026, at an average price of $23.4038 per share, totaling $528,528. The director now owns 10,750 shares, according to an SEC filing.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning NRIX (Nurix Therapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent NRIX coverage spans financial news, earnings and insider activity.
In the last 30 days, NRIX insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($699K). The most active reporter was Hansen Gwenn, Chief Scientific Officer, with 1 filing. 67% of those filings were made under pre-arranged Rule 10b5-1 plans.
Large insider sale could signal reduced confidence.
Analyst upgrades suggest upside potential for NRIX.
Nurix Therapeutics director Gregory Julia P sold 22,560 shares on October 14, 2026, at an average price of $23.4038 per share, totaling $528,528. The director now owns 10,750 shares, according to an SEC filing.
The insider sale may create modest selling pressure on NRIX.
Analyst upgrade with a higher price target may attract buying interest.
AlphAI scores every news story that mentions NRIX with an AI model for sentiment and relevance, and aggregates insider trades from Nurix Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Insiders at Cue Biopharma (CUE), Nurix Therapeutics (NRIX), Flowers Foods (FLO), MarketAxess (MKTX), and Borr Drilling (BORR) made significant trades. Cue's CEO and other executives sold shares, while Borr Drilling's director made large purchases and sales. These moves may influence investor sentiment.
2 min readH.C. Wainwright raised its price target for Nurix Therapeutics (NASDAQ:NRIX) to $36, citing strong Q3 2026 results with $673.1M in revenue and $4.73 EPS. The firm noted increased expenses due to a Roche transaction but highlighted $1.1B in cash reserves. Analysts have mixed views on NRIX's growth potential, with price targets ranging from $33 to $41.
2 min readNurix Therapeutics director Gregory Julia P sold 22,560 shares on October 14, 2026, at an average price of $23.4038 per share, totaling $528,528. The director now owns 10,750 shares, according to an SEC filing.
1 min readGREGORY JULIA P sold 22,583 shares of Nurix Therapeutics, Inc. (NRIX) at $23.40 ($0.53M total) on 2026-10-14.
1 min readRBC Capital maintained an Outperform rating on Nurix Therapeutics with a $35 price target, suggesting a 57.9% upside from the Oct 12 close. The firm cited encouraging clinical data for bexobrutideg and a strong pipeline with a $1.1 billion cash position. Recent analyst price targets range from $32 to $34.
1 min readTruist Securities kept a Buy rating on Nurix Therapeutics with a $33 price target, suggesting a 48.9% upside from the Oct 12 close. The firm cited progress in the company's lead drug candidate and a strong financial position with $1.1 billion in cash.
1 min readNeedham reaffirmed a Buy rating on Nurix Therapeutics with a $34 price target, suggesting a 53.4% upside from its Oct 12 close. The firm cites strong partnerships with Roche and Gilead, and positive clinical progress for its lead candidate, Bexobrutideg, in cancer and inflammatory disease trials.
1 min readNurix Therapeutics, Inc. (NRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL Advanced bexobruti
2 min readNurix Therapeutics' average price target increased from $33.93 to $34.36 by 14 analysts, with a range of $25 to $45. This implies a 55% upside from the Oct. 12 closing price. The consensus rating remains 'Buy' with 13 Buys, 1 Hold, and 0 Sells.
1 min readNurix Therapeutics reported Q3 2026 results, highlighting clinical trial progress and collaborations. The company dosed the first patient in a Phase 3 trial for bexobrutideg, advanced NX-1607 into Phase 1b, and earned $27M from collaborations. Nurix has $1.1B in cash, with a runway into 2029. The company also discontinued development of NX-2127.
3 min read
